In addition, the NPs showed neuroprotective potential, improved memory and cholinergic deficits, and reduced the level of pathological markers in the hippocampus of animal models of AD (including Aβ, BACE-1 (APP processing), p-tau, and oxidative stress markers), suggesting high potential as a targeted system for AD treatment. This evidence concerns the gene MAPT and Alzheimer disease.